Bank of America Has Lowered Expectations for Agilent Technologies (NYSE:A) Stock Price

Agilent Technologies (NYSE:A) had its price objective cut by Bank of America from $153.00 to $150.00 in a research report issued on Friday,Benzinga reports. The firm presently has a “neutral” rating on the medical research company’s stock. Bank of America‘s target price points to a potential upside of 8.58% from the stock’s current price.

A has been the subject of several other research reports. JPMorgan Chase & Co. lowered their price target on shares of Agilent Technologies from $165.00 to $160.00 and set an “overweight” rating for the company in a research report on Tuesday, November 26th. StockNews.com cut shares of Agilent Technologies from a “buy” rating to a “hold” rating in a research report on Tuesday, November 26th. Stifel Nicolaus reaffirmed a “buy” rating and set a $151.00 price target on shares of Agilent Technologies in a report on Monday, August 26th. Wells Fargo & Company decreased their price objective on Agilent Technologies from $157.00 to $155.00 and set an “overweight” rating for the company in a report on Monday. Finally, Barclays cut their target price on Agilent Technologies from $145.00 to $135.00 and set an “underweight” rating on the stock in a research note on Wednesday, November 27th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $143.36.

Agilent Technologies Stock Down 2.0 %

NYSE A traded down $2.76 on Friday, hitting $138.15. 309,085 shares of the stock traded hands, compared to its average volume of 1,716,960. The company has a market capitalization of $39.69 billion, a P/E ratio of 31.15, a price-to-earnings-growth ratio of 4.48 and a beta of 1.07. The stock has a 50-day moving average of $136.87 and a 200 day moving average of $136.60. The company has a current ratio of 2.09, a quick ratio of 1.58 and a debt-to-equity ratio of 0.57. Agilent Technologies has a twelve month low of $124.16 and a twelve month high of $155.35.

Agilent Technologies (NYSE:A) last released its quarterly earnings data on Monday, November 25th. The medical research company reported $1.46 earnings per share for the quarter, topping the consensus estimate of $1.41 by $0.05. The firm had revenue of $1.70 billion for the quarter, compared to analyst estimates of $1.67 billion. Agilent Technologies had a net margin of 19.80% and a return on equity of 25.43%. Agilent Technologies’s quarterly revenue was up .8% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.38 earnings per share. As a group, analysts expect that Agilent Technologies will post 5.56 earnings per share for the current fiscal year.

Insider Activity at Agilent Technologies

In other news, SVP Dominique Grau sold 9,990 shares of the business’s stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $145.00, for a total transaction of $1,448,550.00. Following the transaction, the senior vice president now owns 40,011 shares in the company, valued at approximately $5,801,595. The trade was a 19.98 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Institutional Investors Weigh In On Agilent Technologies

A number of institutional investors have recently bought and sold shares of the business. Livelsberger Financial Advisory acquired a new stake in Agilent Technologies in the 3rd quarter valued at $28,000. Crewe Advisors LLC boosted its stake in shares of Agilent Technologies by 114.8% in the 2nd quarter. Crewe Advisors LLC now owns 189 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 101 shares in the last quarter. Ashton Thomas Securities LLC bought a new stake in shares of Agilent Technologies in the 3rd quarter worth about $31,000. Ridgewood Investments LLC acquired a new stake in shares of Agilent Technologies during the 2nd quarter worth about $29,000. Finally, Fortitude Family Office LLC lifted its holdings in Agilent Technologies by 68.3% during the 3rd quarter. Fortitude Family Office LLC now owns 234 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 95 shares during the last quarter.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.